Entresto Risk Sharing Could Equate To 8.6% Discount, ICER Says; Is Express Scripts Interested?
This article was originally published in The Pink Sheet Daily
Executive Summary
Cost effectiveness report on Novartis’ new heart failure drug includes a hypothetical risk-sharing payment model using hospitalization or death as patient endpoints; Express Scripts exec notes outcomes-based contracts have been problematic but hints at potential for Entresto.